bioRxiv Science⌕ Search

Biology subjects

Etani, H.

Publications and source records attributed to Etani, H..

2 recordsLinked to original sources

Noradrenaline and microglia maintain plasticity-rigidity balance to safeguard rapid emotional learning in the prefrontal cortex

Synaptic plasticity is governed by rules that determine how patterns of neural activity are converted into changes in synaptic weights. While neocortical plasticity rules appear to shift from Hebbian to three-factor forms during development, the cellular mechanisms underlying this transition remain unclear. Here, we show that microglia mediate the developmental transition of plasticity rules at individual dendritic spines in the medial prefrontal cortex (mPFC) during juvenile-to-adolescent maturation. After maturation, microglia suppressed Hebbian activity-induced spine enlargement via a humoral factor. This suppression was relieved by noradrenaline through microglia-intrinsic cAMP signaling, thereby enabling a three-factor rule for gating plasticity. The adolescent mPFC required three-factor plasticity signaling for the acquisition of socially learned fear. Local microglial ablation enhanced learning efficiency but also altered pain sensitivity in a learning-dependent manner, suggesting that microglial suppression safeguards pre-existing emotional circuits. Together, these findings identify microglia as critical regulators of developmental plasticity-rule transitions in the mPFC.

neuroscience↗

Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils

Microglia, the primary immune cells of the central nervous system, play a crucial role in maintaining brain homeostasis through phagocytosis of various substrates, including amyloid-{beta} (A{beta}) fibrils, a hallmark of Alzheimer disease (AD) pathology. However, the molecular mechanisms regulating microglial A{beta} uptake remain poorly understood. Here, we identified GPR34, a Gi/o-coupled receptor highly expressed in microglia, as a novel regulator of fibrillar A{beta} phagocytosis. Treatment with a selective GPR34 agonist, M1, specifically enhanced uptake of A{beta} fibrils, but not its monomer or oligomer, in both mouse and human microglia. Mechanistically, M1 reduced intracellular cAMP levels, which inversely correlated with A{beta} uptake activity. Importantly, a single intrahippocampal injection of M1 in an AD mouse model significantly increased microglial A{beta} uptake in vivo. Furthermore, single-nucleus RNA-sequencing analysis of Japanese AD patient samples revealed a significant reduction of GPR34 expression in microglia from AD patients compared to controls. We also observed an age-dependent decline in microglial GPR34 expression in both human and mouse datasets, suggesting a potential contribution of GPR34 downregulation to age-related A{beta} accumulation and AD risk. Collectively, our findings identify GPR34 as a promising target for modulating microglial A{beta} clearance and highlight the therapeutic potential of GPR34 agonists in AD. Significance statementAlzheimer disease (AD) is characterized by amyloid-{beta} (A{beta}) accumulation in the brain. Microglia, the brains immune cells, play a crucial role in the metabolism of A{beta}. We discovered that activating the microglial receptor GPR34 with a selective agonist enhances the phagocytosis of A{beta} fibrils, a key pathogenic form of A{beta}. Importantly, GPR34 expression decreases with aging and AD progression, potentially contributing to impaired A{beta} clearance. Our findings highlight GPR34 as a promising therapeutic target for AD, as boosting its activity could promote A{beta} clearance and slow disease progression. This study provides valuable insights into microglial function in AD and offers a novel strategy for developing disease-modifying therapies.

neuroscience↗